Follow
Gordon Rustin
Gordon Rustin
Professor of Cancer Therapy
Verified email at nhs.net
Title
Cited by
Cited by
Year
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations
AR Padhani, G Liu, D Mu-Koh, TL Chenevert, HC Thoeny, T Takahara, ...
Neoplasia 11 (2), 102-125, 2009
24172009
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
22352012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
17942014
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
9862015
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)
AK Kakkar, MN Levine, Z Kadziola, NR Lemoine, V Low, HK Patel, ...
Journal of Clinical Oncology 22 (10), 1944-1948, 2004
9072004
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie, A Lamont, ...
The Lancet 376 (9747), 1155-1163, 2010
7772010
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ...
International Journal of Gynecologic Cancer 21 (2), 2011
6702011
Phase i trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
ES Newlands, GRP Blackledge, JA Slack, GJ Rustin, DB Smith, NS Stuart, ...
British journal of cancer 65 (2), 287-291, 1992
6531992
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ...
British journal of cancer 92 (9), 1599-1610, 2005
6182005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ...
The Lancet 366 (9482), 293-300, 2005
603*2005
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG …
A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ...
Annals of oncology 16, viii7-viii12, 2005
5572005
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo …
JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 17 (11), 1579-1589, 2016
5062016
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
GJ Rustin, AE Nelstrop, P McClean, MF Brady, WP McGuire, WJ Hoskins, ...
Journal of Clinical Oncology 14 (5), 1545-1551, 1996
4551996
Role of tumour markers in monitoring epithelial ovarian cancer
T Meyer, GJS Rustin
British journal of cancer 82 (9), 1535-1538, 2000
4512000
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
MJ DUFFY, JM BONFRER, J Kulpa, GJS Rustin, G Soletormos, GC Torre, ...
International Journal of Gynecologic Cancer 15 (5), 2005
4422005
Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis
SM Galbraith, MA Lodge, NJ Taylor, GJS Rustin, S Bentzen, JJ Stirling, ...
NMR in Biomedicine: An International Journal Devoted to the Development and …, 2002
4142002
Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study
GJS Rustin, AE Nelstrop, MK Tuxen, HE Lambert
Annals of oncology 7 (4), 361-364, 1996
4141996
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
M Bower, ES Newlands, L Holden, D Short, C Brock, GJ Rustin, ...
Journal of Clinical Oncology 15 (7), 2636-2643, 1997
3931997
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results
GJS Rustin, SM Galbraith, H Anderson, M Stratford, LK Folkes, L Sena, ...
Journal of clinical oncology 21 (15), 2815-2822, 2003
3912003
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
SM Galbraith, RJ Maxwell, MA Lodge, GM Tozer, J Wilson, NJ Taylor, ...
Journal of clinical oncology 21 (15), 2831-2842, 2003
3892003
The system can't perform the operation now. Try again later.
Articles 1–20